RNAZ · Transcode Therapeutics, Inc.
$1.70
+0.00 (+0.00%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.78M
Shares
16.93M
Volume · Oct 19
29.32K
Avg daily vol (3M)
53.32K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.70
Open$1.70
Day$1.66–1.84
52W close$1.55–14.76
Avg vol 30d47K
Short int52K · 0.3% float · 1.0d
Short vol57%
Last earningsApr 1, 2022
DataJul 2021–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$42.83M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.8%
Year over year · more shares
Price change (1Y)
-88.6%
Trailing year
Short interest
0.3%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−20%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−80%
trailing
YTD return
−75%
this year
Relative strength
−88%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
1 of 8 funds reported for Sep 30 · net +8 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.31% of float · ▼ -15.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Squeeze score
36
low risk · 0–100
Fundamentals
EPS growth
+96%
Y/Y
Free cash flow
$-19.5M
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
12.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
1 of 8 funds reported for Sep 30 · net +8 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.31% of float · ▼ -15.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 1%
Range high $15
vs 200-day avg -73%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNAZ
this stock
Transcode Therapeutics, Inc.
|
$28.78M | -75.1% | — | — | 0.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.73B | +10.7% | +46.2% | 29.4 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +1.3% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNAZ | +4.3% | -3.4% | -80.1% | +1.2% | -75.1% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +5.8% | -2.5% | -87.8% | +0.7% | -87.5% |